Nedd8-Activating Enzyme Inhibitor MLN4924 Provides Synergy with Mitomycin C through Interactions with ATR, BRCA1/BRCA2, and Chromatin Dynamics Pathways
The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
MLN4924 is an investigational small-molecule inhibitor of the Nedd8-activating enzyme currently in phase I clinical trials. MLN4924 induces DNA damage via rereplication in most cell lines. This distinct mechanism of DNA damage may affect its ability to combine with standard-of-care agents and may affect the clinical development of MLN4924. As such, we studied its interaction with other DNA-damaging agents. Mitomycin C, cisplatin, cytarabine, UV radiation, SN-38, and gemcitabine demonstrated synergy in combination with MLN4924 in vitro. The combination of mitomycin C and MLN4924 was shown to be synergistic in a mouse xenograft model. Importantly, depletion of genes within the ataxia telangiectasia and Rad3 related (ATR) and BRCA1/BRCA2 pathways, chromatin modification, and transcription-coupled repair reduced the synergy between mitomycin C and MLN4924. In addition, comet assay demonstrated increased DNA strand breaks with the combination of MLN4924 and mitomycin C. Our data suggest that mitomycin C causes stalled replication forks, which when combined with rereplication induced by MLN4924 results in frequent replication fork collisions, leading to cell death. This study provides a straightforward approach to understand the mechanism of synergy, which may provide useful information for the clinical development of these combinations. Mol Cancer Ther; 13(6); 1625–35. ©2014 AACR.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Drug combination studies and their synergy quantification using the Chou-Talalay method
Chou, T.-C. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-1947 · Cited by 5,739 · cited 2×
“To quantify the synergy, the combination index (16) or nonlinear blending (17) was computed.”
MethodAn inhibitor of NEDD8-activating enzyme as a new approach to treat cancer
Soucy, T. A., Smith, P. G., Milhollen, M. A., Berger, A. J., Gavin, J. M., Adhikari, S., Brownell, J. E., Burke, K. E., Cardin, D. P., Critchley, S., et al. (2009) · Nature · doi:10.1038/nature07884 · Cited by 1,990 · cited 1×
“MLN4924 is being developed as an inhibitor of the Nedd8-activating enzyme (1) and is currently in phase I clinical trials.”
BackgroundSelf-citationSchlacher, K., Wu, H., & Jasin, M. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.05.015 · Cited by 936
The cell-cycle checkpoint kinase Chk1 is required for mammalian homologous recombination repair
Sørensen, C. S., Hansen, L. T., Dziegielewski, J., Syljuåsen, R. G., Lundin, C., Bartek, J., & Helleday, T. (2005) · Nature Cell Biology · doi:10.1038/ncb1212 · Cited by 666 · cited 5×
“Chk1 has been shown to promote homologous recombination by phosphorylation of Rad51 (27, 28), although wedonot see any changes in thephosphorylation status of Rad51 (Fig.”
BackgroundInfluentialGroisman, R., Kuraoka, I., Chevallier, O., Gaye, N., Magnaldo, T., Tanaka, K., Kisselev, A. F., Harel-Bellan, A., & Nakatani, Y. (2006) · Genes & Development · doi:10.1101/gad.378206 · Cited by 268 · cited 9×
“Ddb1 is a core component of the Cul4A and Cul4B E3 ubiquitin ligases, so loss of DDB1 should mimic the effect ofMLN4924 onCul4A/B activity and the addition of MLN4924 would not enhance the synergy already experienced by depletion of DDB1.”
BackgroundInfluentialThe p400 ATPase regulates nucleosome stability and chromatin ubiquitination during DNA repair
Xu, Y., Sun, Y., Jiang, X., Ayrapetov, M. K., Moskwa, P., Yang, S., Weinstock, D. M., & Price, B. D. (2010) · Journal of Cell Biology · doi:10.1083/jcb.201001160 · Cited by 194
Cited by
Targeting DNA Repair in Cancer: Beyond PARP Inhibitors
Brown, J. S., O'Carrigan, B., Jackson, S. P., & Yap, T. A. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-0860 · Cited by 618
Exploiting replicative stress to treat cancer
Dobbelstein, M., & Sørensen, C. S. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4553 · Cited by 302
Protein neddylation and its role in health and diseases
Zhang, S., Yu, Q., Li, Z., Zhao, Y., & Sun, Y. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01800-9 · Cited by 171
“409 For example, MLN4924 sensitizes ovarian cancer cells to cisplatin even in cisplatin-resistant ovarian cancer cells by increasing the levels of pro-apoptotic protein, BIK and inducing DNA damage and oxidative stress both in cell culture model and in mice bearing ovarian tumor xenografts.”
BackgroundTargeting DNA Replication Stress for Cancer Therapy
Zhang, J., Dai, Q., Park, D., & Deng, X. (2016) · Genes · doi:10.3390/genes7080051 · Cited by 102
“Neddylation can be inhibited by targeting NEDD8-activating enzyme (NAE), a ubiquitin-like protein, using MLN4924 [82–84], which has just completed a phase I clinical trial [50] (Table 1).”
BackgroundInfluentialBenamar, M., Guessous, F., Du, K., Corbett, P., Obeid, J., Gioeli, D., Slingluff, C. L., & Abbas, T. (2016) · eBioMedicine · doi:10.1016/j.ebiom.2016.06.023 · Cited by 77
Metadata
- Authors
- Garcia, K., Blank, J. L., Bouck, D. C., Liu, X. J., Sappal, D. S., Hather, G., Cosmopoulos, K., Thomas, M. P., Kuranda, M., Pickard, M. D., Liu, R., Bandi, S., Smith, P. G., & Lightcap, E. S.
- Venue
- Molecular Cancer Therapeutics
- Published
- 2014-06-01
- Volume
- 13
- Issue
- 6
- Pages
- 1625-1635
- ISSN
- 1535-7163 (ISSN-L)
- 1538-8514
- OpenAlex
- W2105560882
- Cited by
- 51
- References
- 6
- FWCI
- 3.04
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Nedd8-Activating Enzyme Inhibitor MLN4924 Provides Synergy with Mitomycin C through Interactions with ATR, BRCA1/BRCA2, and Chromatin Dynamics Pathways. https://app.cochat.ai/papers/10.1158/1535-7163.mct-13-0634
- The paper
- Garcia, K., Blank, J. L., Bouck, D. C., Liu, X. J., Sappal, D. S., Hather, G., Cosmopoulos, K., Thomas, M. P., Kuranda, M., Pickard, M. D., Liu, R., Bandi, S., Smith, P. G., & Lightcap, E. S. (2014). Nedd8-Activating Enzyme Inhibitor MLN4924 Provides Synergy with Mitomycin C through Interactions with ATR, BRCA1/BRCA2, and Chromatin Dynamics Pathways. Molecular Cancer Therapeutics. https://doi.org/10.1158/1535-7163.mct-13-0634
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.